Schrodinger SDGR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Software | $136.47M-8.1% | $148.5M-6.6% | $158.94M+4.2% | $152.6M-0.5% | $153.32M+6.9% | |
| Total revenues by Product | ||||||
| Hosted software | $46.33M+2.7% | $45.12M+0.8% | $44.76M+6.6% | $41.99M+7.8% | $38.95M+10.5% | |
| On-premise software | $90.21M-11.1% | $101.45M-9.8% | $112.49M+3.4% | $108.81M-2.7% | $111.82M+7.5% | |
| Professional services | $10.41M+7.8% | $9.65M+18.1% | $8.17M-5.2% | $8.62M-3.8% | $8.95M-8.6% | |
| Software maintenance | $27.16M-0.5% | $27.29M+3.8% | $26.29M+4.7% | $25.12M+3.9% | $24.18M+3.9% | |
| Software products and services | $186.24M-4.8% | $195.66M-5.0% | $206.04M+4.6% | $197.06M+2.7% | $191.92M+6.4% | |
| Drug discovery services revenue from contracts with customers by Product | ||||||
| Drug Discovery Services | $56.22M+11.9% | $50.22M+23.2% | $40.78M+33.3% | $30.58M+8.6% | $28.15M+12.0% | |
| Receivable, after allowance for credit loss, current by Product | ||||||
| Oncology, Neurology, and Immunology Product | $0— | $0— | $0— | —— | —— | |
| Software contribution | $0— | $0-100% | $150M— | —— | —— | |
| Restricted cash (includes related party amounts of $0 and $72, respectively) by Product | ||||||
| Software contribution | $8.06M-37.4% | $12.89M-40.0% | $21.49M— | —— | —— | |
| Total revenues by Geography | ||||||
| APAC | $72.25M-3.9% | $75.16M-23.2% | $97.87M+12.1% | $87.29M+5.9% | $82.44M+23.9% | |
| EMEA | $26.78M+2.3% | $26.18M+0.3% | $26.11M+6.0% | $24.64M-3.3% | $25.47M+2.3% | |
| Rest of World | $1.16M-25.5% | $1.56M-6.5% | $1.67M+19.4% | $1.4M+4.0% | $1.35M+10.4% | |
| United States | $154.71M+1.1% | $152.96M+16.5% | $131.3M+5.4% | $124.59M+2.8% | $121.24M+5.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Schrodinger break its business down?
- Schrodinger (SDGR) reports gross profit by business across 2 parts — Drug Discovery and Software. Each is extracted from the segment footnotes and tracked over time.
- Where does Schrodinger's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Schrodinger's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
